To begin with, in a phase I-II study (NCT00902044) conducted by Ahmed et al. [20], HER2-CAR-T cells were used in order to treat 19 patients with HER2-positive sarcomas, of which 16 were osteosarcomas, 1 was a primitive neuroectodermal tumor, 1 was Ewing sarcoma, and 1 was a protofibroblastic small round cell tumor. The gene discussed is ERBB2; the disease is primitive neuroectodermal tumor.